Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs
November 23 2016 - 12:00PM
Agreement addresses future production needs of
IFNα, key component of IFN Kinoid1
Neovacs (Alternext Paris:ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases,
today announced a partnership with 3P Biopharmaceuticals, a leader
in the production of biological drugs, for the manufacture of
interferon alpha (IFNα). Today’s collaboration follows the recent
acquisition of the technology for the manufacture of IFNα by
Neovacs from AMEGABIOTECH.
This license agreement will allow Neovacs to
directly transfer AMEGABIOTECH's technology to the production site
of 3P Biopharmaceuticals, which will ensure the manufacture of the
IFNα cytokine. As the only Spanish manufacturer of biological
products in the healthcare field, 3P Biopharmaceuticals has a
successful track record working with top pharma and biotech
companies throughout Europe and the United States.
Miguel Sieler, CEO of Neovacs,
said, “This partnership is in line with the recent license
agreement signed with AMEGABIOTECH. The completion of these two
steps allows us to secure the complete production chain for the
manufacture of IFNα, one of the primary raw materials of our most
advanced product, IFNα Kinoid. In addition, the agreement
complements the partnership signed earlier this year with Stellar
Biotechnologies, the supplier of the other main component of our
vaccine IFNα Kinoid, Keyhole Limpet Hemocyanin (KLH). Within the
framework of this partnership, Stellar Biotechnologies holds 30% of
Neostell, the production subsidiary of Neovacs.”
Elena Erroba, Business Development
Director of 3P Biopharmaceuticals, affirmed:
“3P Biopharmaceuticals is very happy with this collaboration.
It will allow 3P Biopharmaceuticals to contribute to a very
innovative therapeutic approach, with our strong competence in the
field of manufacturing high quality protein.”
_____________________________1 IFNα Kinoid:
Therapeutic vaccine from Neovacs technology, which is composed of
the targeted cytokine IFNα, conjugated with a carrier protein,
Keyhole Limpet Hemocyanin.
About 3P Biopharmaceuticals3P
Biopharmaceuticals is a leading European CDMO specialized in the
process development and GMP manufacturing of biologics and cell
therapy products in mammalian, microbial and yeast expression
systems. With a highly qualified team of experts, 3P supports its
clients offering manufacturing related drug development solutions
from initial research, through preclinical and clinical trials to
commercialization. 3P was created and promoted by a group of
shareholders and institutions with large expertise in the
biotechnology and pharmaceutical sector. Thanks to their financial
effort and full confidence, 3P has been able to consolidate its
activity into the international market and has become a reference
for the biotech sector.http://www.3pbio.com/
About Neovacs TechnologyNeovacs
targets pathologies associated with an overproduction of endogenous
cytokines. This technology is based on active immunotherapy to
generate an immune response through the administration of an
immunogenic complex involving the target cytokine to a carrier
protein. The intramuscular injection of this Kinoid induces an
immune response and stimulates the production of polyclonal
antibodies against the target cytokines. It is thus possible to
block cytokine overproduction and its biological effects. Several
autoimmune and inflammatory diseases (Type 1 diabetes, systemic
lupus erythematosus, psoriasis, etc.) are characterized by a
disorder of cytokines that are found produced in excess (ex:
IFNα). This overproduction will promote inflammation and
dysregulation of the immune system.
About NeovacsListed on
Alternext Paris since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company’s proprietary
technology for inducing a polyclonal immune response (covered by
five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα Kinoid, an
immunotherapy being developed for the indication of lupus,
dermatomyositis and also in preclinical trial for Type 1 diabetes.
Neovacs is also conducting preclinical development works on other
therapeutic vaccines in the fields of auto-immune diseases,
oncology and allergies. The goal of the Kinoid approach is to
enable patients to have access to safe treatments with efficacy
that is sustained in these life‑long diseases. www.neovacs.fr
Contacts
NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communications Germany – MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2023 to Jul 2024